Detecting and treating subdurals is challenging. Current care pathways are complex and rely on manual identification and triage.
Due to the aging population and use of anticoagulation, subdurals are projected to become the most common cranial surgical pathway.
Alerting the entire care team can take time and any delay in the workflow can significantly increase morbidity and mortality.
It’s challenging for spokes to share imaging with hubs as well as coordinate care for patients being referred or transferred.
132% higher than non-recurrent, resulting in 2030 projected costs of $4.8B for the US.1
Viz SUBDURAL uses AI-powered alerts to promote collaboration among the entire care team to coordinate care, increase access to treatment and lower hospital costs.
Automatic detection of suspected acute and chronic subdurals
Review patient scans with the hyperfast 3D image viewer from mobile, desktop or radiology workflow
Examine detailed patient information and receive immediate updates as patient status changes as soon as it’s entered into the app or EHR
Coordinate care across teams and hospitals in a HIPAA-compliant environment
Viz SUBDURAL allows us to detect both acute and chronic subdural hemorrhages to better identify early treatment pathways. Having an algorithm that identifies both can allow us to take better care of our patients.
Benefits of AI in your workflow
Automatically identify acute and chronic subdural bleeds, then quickly notify the care team to mobilize in case an immediate intervention is necessary.
Viz SUBDURAL optimizes your existing workflow by activating the right team member at the right time with the right information.
Transfer data seamlessly through the secure, cloud-native platform and connect with the entire care team, minimizing treatment delays.
There is a growing healthcare burden related to Chronic Subdural Hematoma (cSDH). Recurrence is common and treatment costs for recurrent cSDHs is 132% higher than the treatment cost of non-recurrent. Clinical trials are investigating promising new cSDH treatments that positively impact hospital costs.
Current treatment methods associated with a higher total hospital cost compared to new treatment options
The treatment cost for recurrent CSDHs was 132% higher than the treatment cost of non-recurrent
2030 cost of cSDH hospitalization in the US expected to be $4.8 billion3
*Derived from projected incidence of cSDH in 2030 and hospital costs adjusted to 2% inflation to 2030.
.png)
